how long have glp 1 agonists been around Timeline of GLP-1 discovery and clinical development. (a) Key events in... GLP-1 Agonists Market Report 2025-2033,

Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA

Shocking Truth: Compounded GLP-1s on Groupon pose serious health risks

Public Citizen contends that Novo Nordisk and Eli Lilly's obesity drugs are straining budgets so much that generics should be authorized.

Research suggests that foods, such as eggs, vegetables, and olive oil, may help increase GLP-1 levels

Introduced in the twenty-first century, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of antidiabetic drugs noted not only for their potent glucose-lowering effects but also for their cardiovascular and renal protective benefits

In an investigative report in partnership with KFF Health News, NBC News Anne Thompson reports on the growing cases of overdoses involving GLP-1 weight loss drugs.